Form 4: Recursion Pharmaceuticals Executive Najat Khan Reports Stock Transactions
SEC Form 4
Najat Khan, Chief R&D Commercial Officer at Recursion Pharmaceuticals, reports acquisition and disposal of Class A Common Stock and stock options.
Summary
- Najat Khan, a Director and Officer at Recursion Pharmaceuticals, filed a Form 4 detailing changes in beneficial ownership.
- On February 3, 2025, Khan acquired 210,113 shares of Class A Common Stock at $0 and 8,049 shares of Class A Common Stock at $0.
- On the same day, Khan disposed of 2,753 shares of Class A Common Stock at $7.25 to cover tax obligations.
- Khan also acquired 420,226 stock options with an exercise price of $7.25, expiring on February 3, 2035.
- Following these transactions, Khan beneficially owns 712,381 shares of Class A Common Stock and 1,414,170 stock options.
- Some of the acquired RSUs vest in installments starting May 15, 2025, and some of the options vest in installments starting March 1, 2025 and July 1, 2025.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine filing of stock transactions. The acquisition of shares and options is mildly positive, while the disposal for tax obligations is neutral.
Positives
- The acquisition of shares and stock options by a company executive can be seen as a positive sign of confidence in the company's future.
Negatives
- The disposal of shares to cover tax obligations is a routine transaction and doesn't necessarily indicate a negative outlook.
Risks
- Executive stock transactions are subject to insider trading regulations, and any violations could result in legal and reputational risks.
- The value of stock options is dependent on the future performance of the company's stock, which is subject to market risks.
Future Outlook
The document does not contain explicit forward-looking statements, but the vesting schedules of the RSUs and stock options suggest a long-term commitment from the executive.
Industry Context
Executive stock transactions are common in publicly traded companies and are closely monitored by investors for insights into management's confidence in the company's prospects.
Stakeholder Impact
- The transactions may have a minor impact on shareholders by slightly diluting the stock or signaling confidence from an executive.
Key Dates
| Date | Description |
|---|---|
| 02/03/2025 | Date of earliest transaction: acquisition and disposal of shares and acquisition of stock options. |
| 02/03/2035 | Expiration date of stock options. |
| 05/15/2025 | Initial vesting date for some RSUs. |
| 03/01/2025 | Initial vesting date for some stock options. |
| 07/01/2025 | Initial vesting date for some stock options. |
| 08/01/2034 | Expiration date of stock options. |
| 02/05/2025 | Date of Form 4 filing. |
Keywords
Form 4, beneficial ownership, stock options, Class A Common Stock, Najat Khan, Recursion Pharmaceuticals, RXRX, executive compensation, insider trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.